Scholarlink

<p>The CARMA1–BCL10–MALT1 (CBM) complex plays a pivotal role in mediating antigen receptor-induced activation of NF-κB, a pathway critical for lymphocyte survival and proliferation. In aggressive lymphoid malignancies such as activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), oncogenic mutations drive constitutive CBM complex activation, leading to chronic NF-κB signaling and treatment resistance. Traditional therapeutic approaches have focused on inhibiting MALT1’s protease activity; however, these strategies incompletely suppress CBM-driven signaling and may provoke immune-related toxicities by selectively impairing regulatory T cell function. Recent insights into the structural basis of CBM assembly have identified the BCL10–MALT1 interaction, particularly the hydrophobic groove between MALT1’s Ig1–Ig2 domains, as a critical therapeutic target. Small-molecule inhibitors such as M1i-124 have demonstrated the ability to disrupt this interaction, leading to dual inhibition of MALT1’s scaffolding and protease activities, destabilization of the CBM complex, and selective toxicity toward ABC-DLBCL cells. Preclinical studies show promising efficacy with broad suppression of NF-κB signaling and cytokine production while minimizing off-target effects. This review highlights the biological rationale, preclinical progress, and future directions for targeting the BCL10–MALT1 interface, outlining a transformative strategy for precision therapy in lymphoma and other CBM-dependent diseases. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breaking the oncogenic link: BCL10–MALT1 disruption as a precision strike against NF-κB-driven lymphomas

  • 期刊论文

  • 发表日期：

    2025年7月19日

查看全文
  • Emadeldin M. Kamel,
  • Sally Mostafa Khadrawy,
  • Ahmed A. Allam,
  • Noha A. Ahmed,
  • Faris F. Aba Alkhayl,
  • Al Mokhtar Lamsabhi

摘要

The CARMA1–BCL10–MALT1 (CBM) complex plays a pivotal role in mediating antigen receptor-induced activation of NF-κB, a pathway critical for lymphocyte survival and proliferation. In aggressive lymphoid malignancies such as activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), oncogenic mutations drive constitutive CBM complex activation, leading to chronic NF-κB signaling and treatment resistance. Traditional therapeutic approaches have focused on inhibiting MALT1’s protease activity; however, these strategies incompletely suppress CBM-driven signaling and may provoke immune-related toxicities by selectively impairing regulatory T cell function. Recent insights into the structural basis of CBM assembly have identified the BCL10–MALT1 interaction, particularly the hydrophobic groove between MALT1’s Ig1–Ig2 domains, as a critical therapeutic target. Small-molecule inhibitors such as M1i-124 have demonstrated the ability to disrupt this interaction, leading to dual inhibition of MALT1’s scaffolding and protease activities, destabilization of the CBM complex, and selective toxicity toward ABC-DLBCL cells. Preclinical studies show promising efficacy with broad suppression of NF-κB signaling and cytokine production while minimizing off-target effects. This review highlights the biological rationale, preclinical progress, and future directions for targeting the BCL10–MALT1 interface, outlining a transformative strategy for precision therapy in lymphoma and other CBM-dependent diseases.